BioSim

What BioSim does

BioSim (Asociación Española de Medicamentos Biosimilares / Spanish Association of Biosimilar Medicines) is a non-profit industry association founded in November 2015 and headquartered in Madrid, Spain (Calle Condesa de Venadito, 1). It represents approximately 16 pharmaceutical companies established in Spain that research, develop, produce, and/or commercialize biosimilar medicines, including Amgen, Biocon, Biogen, Celltrion, Fresenius Kabi, Gedeon Richter, Kern Pharma, mAbxience, Pfizer, Qilu, Rovi, Samsung Bioepis, Sandoz, Sanofi, Stada, and Teva.

The association operates as a knowledge hub and advocacy platform rather than a product company. Its core outputs are an online information portal (biosim.es), an annual National Biosimilars Conference (Jornada Nacional de Biosimilares, with the VI Jornada held November 21, 2024 and VII scheduled June 4, 2026), a weekly newsletter, formal reports and budget impact analyses (including a 2020-2030 budget impact analysis of biosimilars in the Spanish National Health System), patient-facing educational resources, and training programs developed in partnership with medical societies and universities. Notable outputs documented in source material include healthcare system savings attributed to biosimilars exceeding €1,800 million in 2023 and reports that biosimilars advance biological treatment adoption by 19 months.

The business model is membership-funded. BioSim generates no commercial revenue from product sales; operations are sustained by member-company dues. Governance sits with a Board of Directors chaired by Joaquín Rodrigo (re-elected October 2023) and led by Director General Encarnación Cruz (appointed June 2020 following the passing of founding Director General Regina Mázquiz). The organization maintains 15+ formal partnerships with healthcare professional societies (SEOM, SEFH, SEFAP, SEDISA, FACME, OMC, CGCOF), universities (Universidad CEU San Pablo, Universidad Francisco de Vitoria, Universidad Europea), and regional health authorities (Aragón, Extremadura, SERMAS), plus an internal Ethics Commission.

Name

BioSim

Legal name

ASOCIACION ESPAÑOLA DE BIOSIMILARES

Website

https://biosim.es

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

1–10 employees

Short description

BioSim is the Spanish non-profit trade association for biosimilar medicine manufacturers, providing advocacy, policy engagement, and educational resources to its 16+ pharmaceutical company members and Spanish healthcare stakeholders since 2015.

Ownership category

akta.pro rank

Product category

Pharmaceutical Industry Association (Biosimilars Advocacy)

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Biological Products, (No Disgnostic Substances) (2836), Services-Commercial Physical & Biological Research (8731)

akta.pro industry

PRIMARYHLAAAHAJ

Biosimilar Development & Clinical/Regulatory Services (comparability, trials, pharmacovigilance)

Healthcare & Life Sciences/Biotechnology & Biologics/Biosimilars & Biologic Generics

SECONDARYHLAIAFAL

Other Recombinant Protein Biosimilars (non-mAb, non-hormone)

Healthcare & Life Sciences/Pharmaceuticals/Biosimilars

SECONDARYHLAAAJAJ

Bioprocess Facility, Cleanroom & Utility Systems (HVAC, WFI, CIP/SIP, containment)

Healthcare & Life Sciences/Biotechnology & Biologics/Bioprocessing & Biomanufacturing Technology (upstream/downstream, single-use, analytics)

Keywords

• Biosimilar medicines advocacy
• Pharmaceutical industry association
• Healthcare policy education
• Biologic medicines representation
• Biosimilar market research

Headquarters

HQ city

Madrid

HQ country

Spain

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D, Others

Distribution channels1 record

Marketing channels6 records

Core offering

BioSim is a non-profit industry association representing pharmaceutical companies that research, develop, produce, and/or commercialize biosimilar medicines in Spain. It does not sell products or services commercially; instead it delivers advocacy, education, and information services through an online information portal, published reports and budget impact analyses, an annual national conference, professional training programs, patient resources, and a weekly newsletter to advance biosimilar adoption and healthcare sustainability.

Product overview

BioSim (Asociación Española de Biosimilares) is a non-profit association representing pharmaceutical companies that research, develop, produce, and/or commercialize biosimilar medicines in Spain. Rather than offering a unified software product, BioSim provides a portfolio of information, education, and advocacy services including: an online information portal with educational resources and publications; the annual National Biosimilars Conference (Jornada Nacional de Biosimilares); specialized reports and market analyses; patient information resources; and professional training programs developed in collaboration with healthcare societies and academic institutions. The organization serves as a central hub for biosimilar stakeholders, facilitating knowledge exchange, policy advocacy, and market development for biosimilar medicines in Spain.

Differentiator

Problem solved

Functional benefit

Products and services

• National Biosimilars Reports (Informes)

Quantifiable outcome

• Healthcare system savings of more than 1,800 million euros in 2023 from biosimilar medicines
• +2 more outcomes

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

16 partnerships are on record, tiered supporting and core.

• SERMAS (Servicio Madrileño de Salud)supportingStrategic or Co-development Partner · 26 June 2024Collaboration to improve information about biosimilars for healthcare professionals in the Madrid health system.
• SEOM (Sociedad Española de Oncología Médica)coreStrategic or Co-development Partner · 17 October 2023BioSim and SEOM agreed to strengthen knowledge of biosimilars among oncology professionals and cancer patients. Joint collaboration includes educational initiatives and information sharing on biosimilar use in oncology treatments.
• SEFAP (Sociedad Española de Farmacéuticos de Atención Primaria)coreStrategic or Co-development Partner · 2 October 2023BioSim and SEFAP renewed their collaboration agreement for improving training on biosimilar medicines. Joint initiatives include educational programs and professional development for primary care pharmacists.
• Servicio Extremeño de SaludsupportingStrategic or Co-development Partner · 27 February 2023Extremadura became the first autonomous community to implement a Shared Savings Program (Ganancias Compartidas) for biosimilar medicines.
• Escuela Andaluza de Salud PúblicasupportingStrategic or Co-development Partner · 5 October 2022Agreement to analyze the national biosimilar market and collaborate on healthcare public policy research.
• Departamento de Sanidad de AragónsupportingStrategic or Co-development Partner · 4 October 2022Collaboration to analyze opportunities for biosimilar medicines for more effective healthcare management in the Aragon region.
• Universidad CEU San PablosupportingStrategic or Co-development Partner · 22 June 2022University alliance to provide biosimilar education to health sciences students, integrating biosimilar topics into the university curriculum.
• SEFH (Sociedad Española de Farmacéuticos de Hospital)coreStrategic or Co-development Partner · 1 June 2022Collaboration agreement to disseminate information about the role of biosimilars in hospital pharmacy practice.
• CGCOF (Consejo General de Colegios Oficiales de Farmacéuticos)coreStrategic or Co-development Partner · 26 May 2022Joint initiative for greater and better information and training for the nursing profession in biosimilars. Created the 'Biosimilares y Farmacia' YouTube channel with video advice content.
• Universidad EuropeasupportingStrategic or Co-development Partner · 9 December 2021Partnership to promote biosimilar knowledge among university students.
• Universidad Francisco de Vitoria de MadridsupportingStrategic or Co-development Partner · 10 March 2021Partnership to train future healthcare professionals on biosimilar medicines within university education programs.
• SEDISA (Sociedad Española de Directivos de la Salud)coreStrategic or Co-development Partner · 11 December 2018Collaboration framework for developing opportunities that biosimilar medicines offer to the National Health System, focusing on healthcare management and sustainability.
• FACME (Federación de Asociaciones Científico-Médicas de España)coreStrategic or Co-development Partner · 21 March 2018Agreement to improve knowledge about biosimilar medicines and share clinical experience among medical professionals.
• Foro Español de PacientescoreStrategic or Co-development Partner · 13 November 2017Collaboration model aimed at improving knowledge of biosimilar medicines among patients.
• OMC (Organización Médica Colegial de España)coreStrategic or Co-development Partner · 28 September 2017Joint educational programs on biosimilars for doctors, including the 'Guía de Biosimilares para Médicos' (Guide to Biosimilars for Doctors) publication.
• BioSim Ethics CommissioncoreOthers · 6 July 2017Internal advisory body consisting of healthcare professionals and patients that provides ethical recommendations on biosimilar use, interchangeability, and multi-switch policies.

Recent moves6 records

Expansion highlights5 records

Direct peers

• Medicines for Europe: Brussels-based trade association representing the European generic and biosimilar medicines industry. Directly analogous to BioSim in mission (advocacy, market access, regulatory engagement) but operating at the pan-EU level rather than Spain-only.

Regional players

• Association for Accessible Medicines (AAM): US trade association representing generic and biosimilar manufacturers. Mission and advocacy playbook are directly comparable to BioSim, though operating in the US regulatory environment rather than the EU/Spanish one.
• Canadian Generic Pharmaceutical Association (CGPA): Canadian trade association representing generic and biosimilar pharmaceutical manufacturers. Comparable advocacy, policy and education mandate around biosimilar adoption in Canada.
• Pro Biosimilars (ProGenerika): German biosimilars industry working group operating under ProGenerika. Highly analogous to BioSim in Germany — focused advocacy, market data and stakeholder education around biosimilars, but for the German market.
• GBMA (Generic and Biosimilar Medicines Association, Australia): Australian peak industry body for generic and biosimilar medicines manufacturers. Comparable mission — market access, policy advocacy and stakeholder education — in the Australian market.
• British Biosimilars Association (BBA): UK trade body for biosimilar manufacturers, part of the British Generic Manufacturers Association. Closely mirrors BioSim's role in the UK — advocacy, education, and regulatory engagement around biosimilar uptake.

Broad incumbents

• European Federation of Pharmaceutical Industries and Associations (EFPIA): Largest pan-European pharma industry association covering innovative originator companies. Broader than BioSim (which focuses specifically on biosimilars) but engages with the same EU regulatory and policy bodies on biosimilar market access.
• International Generic and Biosimilar Medicines Association (IGBA): Global umbrella association for generic and biosimilar medicines industries, of which BioSim-aligned national associations are members. Provides international coordination, regulatory advocacy and policy frameworks analogous to BioSim's role within Spain.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/biosim_es
• YouTubeyoutube.com/channel/UCTRJBWNActiuechwGlMIaWA
• Facebookfacebook.com/BioSim.es
• LinkedInlinkedin.com/company/biosim

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about BioSim